Company Overview and News

3
Can Portfolio Repositioning Aid HCP Amid Supply Concerns?

2018-09-17 zacks
In a bid to reposition its portfolio, HCP Inc. (HCP - Free Report) has resorted to opportunistic acquisitions and non-core dispositions. The company is reducing its senior housing triple-net footprint and focusing on senior housing operatingportfolio (SHOP). However, rising supply of senior housing assets may reduce the company’s ability to recycle capital out of non-core assets.
HCP WPC VICI

9
September 2018 Stock Considerations

2018-09-14 seekingalpha
A little late with this post as I like to highlight my potential stock buys in the beginning of the month but sometimes it can be tough deciding where to deploy fresh capital when many stocks are trading at premium prices. Of course, we all know that no matter how high the market rises, there will always be a gem in the rough lurking somewhere. With that being said, let's take a look at some of my September stock considerations.
D HCP PPL SBRA SBRAP

17
Lanny's August Dividend Income Summary

2018-09-07 seekingalpha
Just when you thought summer was winding down, I am writing this in blistering heat out there - as it has just about touched 90 degrees here in Northeast Ohio. Last month, I said it was raining dividends, well this month - we are scorching dividends baby! We are now EIGHT months down with FOUR monstrous months left to kick butt. I have been spending even more time to see where things are looking, financially, and let's just say it'll be a grind through the end of the year.
PG CAT HCP HRL KMI CZNC CM SBUX WRK KMR DAL KMRFZ CVB DE

33
Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2018 Update

2018-08-14 seekingalpha - 1
David Abrams’ 13F portfolio value increased this quarter from $3.19B to $3.60B. The number of positions increased from 20 to 22.
PCG HCN ENT TWX HCP GOOG GPI QCP ENTWW UHAL KMI AABA WELL BEN BKS CI KMR CCO LAD AET CVB BNED WU TWC GOOGL SPH KMRFZ ORLY

 
HCP / HCP, Inc. 10-Q (Quarterly Report)

2018-08-02 sec.gov
Document Table of Contents
HCP

 
HCP / HCP, Inc. 8-K (Current Report)

2018-08-02 sec.gov
Document UNITED STATES
HCP

 
HCP / HCP, Inc. 8-K (Current Report)

2018-08-02 sec.gov
Document
HCP

 
REITs to Watch for Q2 Earnings on Aug 2: REG, AIV and HCP

2018-08-01 zacks
The second-quarter earnings season is past the halfway mark with results from 265 S&P 500 members out as of Jul 27. Per the latest Earnings Preview, total earnings of these index members witnessed 23.6% year-over-year (y/y) growth on the back of 10.1% higher revenues. Beat ratios are impressive with 80.8% of the companies beating earnings estimates and 72.1% surpassing revenue expectations. Further, the report indicates that second-quarter earnings for total S&P 500 companies are projected to improve 23.
REG REIS HCP CACC RP

 
Will Rising Healthcare Spending Aid HCP This Earnings Season?

2018-08-01 zacks
HCP Inc. (HCP - Free Report) is slated to report second-quarter 2018 results on Aug 2, before the opening bell. Though the company’s performance will likely reflect a year-over-year decline in funds from operations (FFO), its top-line results are anticipated to display growth. In the last reported quarter, this Irvine, CA-based healthcare REIT delivered a positive surprise of 4.35%, in terms of FFO per share.
VTR HCN HR CACC HCP WELL VTRB

 
Welltower: One Man's Trash

2018-07-26 seekingalpha
QCP's short life is likely coming to an end as shareholders approve the merger with WELL.
HCP WELL QCP

 
A Health Care REIT That Willy Wonka Would Love

2018-07-23 seekingalpha
While some pundits believe that skilled nursing rents will continue to decline, the bulls (like me) argue that the supply and demand fundamentals will drive returns.
UBA 3290 HCP O NHLG OPRF NHC UBP UHT ESS OHI NHI NNN

 
Top REIT Stock Pays 5.4%, Strong FFO Growth, But Wait For A Drop

2018-07-09 seekingalpha
Strong stock performance is the result of above-average FFO and dividend growth throughout the economic cycle.
VTR HCP WELL

1
Hitachi Vantara Named a Leader in IDC MarketScape on Object Storage for the Third Consecutive Time

2018-07-02 globenewswire
SANTA CLARA, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced it has been placed in the Leaders category of the International Data Corporation (IDC) MarketScape: Worldwide Object-based Storage 2018 Vendor Assessment (DOC # US42665518, June 2018) based on its Hitachi Content Platform solution.
HCP

93
July 2018 Stock Considerations

2018-07-02 seekingalpha
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D KMB PEP KHC GNE SBUX CLX

36
HCP Might Sell Senior Housing Assets to Apollo for $428M

2018-06-25 zacks
HCP Inc. (HCP - Free Report) is rumored to be selling the company’s 22 Brookdale-managed senior housing properties for $428 million to New York firm — Apollo Global Management LLC (APO - Free Report) — per a Bloomberg news. Earlier this June, the company announced that it has entered into definitive deals for selling those 22 properties, having 2,781 units, to an institutional investor. This healthcare REIT has been selling several of its senior housing assets in a bid to improve the quality of the company’s senior housing portfolio, strengthen balance sheet and lower the Brookdale Senior Living Inc.
PLD HFC HCP BKD APO EXR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to HCP / HCP, Inc. on message board site Silicon Investor.

United Heritage (UHCP) United Heritage (UHCP) United Heritage (UHCP)
CUSIP: 40414L109